Loading...

Mirati Therapeutics, Inc.

MRTX•NASDAQ
Healthcare
Biotechnology
$58.70
$-0.10(-0.17%)

Mirati Therapeutics, Inc. (MRTX) Stock Overview

Explore Mirati Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.5/100

Key Financials

Market Cap4.1B
P/E Ratio-4.46
EPS (TTM)$-12.18
ROE-0.62%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

MRTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Mirati Therapeutics, Inc. (MRTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.46 and a market capitalization of 4.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for MRTXStats details for MRTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for MRTXAnalyst Recommendations details for MRTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

CEO

Charles M. Baum

Employees

587

Headquarters

3545 Cray Court, San Diego, CA

Founded

2013

Frequently Asked Questions

;